Liju Zong1, Qianqian Zhang2, Yujia Kong3, Fan Yang4, Yuncan Zhou3, Shuangni Yu5, Ming Wu3, Jie Chen6, Youzhong Zhang7, Yang Xiang8. 1. Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China; Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. 2. Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, China; Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Shandong First Medical University, China. 3. Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. 4. Department of Pathology, The Second Affiliated Hospital of Shandong First Medical University, China. 5. Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. 6. Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Electronic address: chenjie@pumch.cn. 7. Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, China. Electronic address: zhangyouzhong@sdu.edu.cn. 8. Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Electronic address: xiangy@pumch.cn.
Abstract
OBJECTIVE: To determine the value of the tumor-stroma ratio (TSR) while identifying prognostic factors in patients with 2018 International Federation of Gynecology and Obstetrics (FIGO) stage IIIC squamous cell carcinoma of the cervix following primary radical surgery. METHODS: Three hundred eighty-four patients with node-positive squamous cell carcinoma of the cervix (2018 FIGO stage IIIC) who underwent radical surgery between January 2005 and December 2016 were included in this retrospective study. The TSRs were assessed on hematoxylin and eosin-stained tumor slides and classified as stroma-low (<50% stroma) or stroma-high (≥50% stroma). RESULTS: Sixty-seven patients were categorized as stroma-high; they had shorter disease-free survival (DFS) and overall survival (OS) periods than did their stroma-low counterparts. On multivariate analysis, a tumor size ≥4 cm, ≥3 metastatic lymph nodes, and stroma-high status were independent predictors of shorter DFS and OS. These factors were incorporated into a prognostic scoring system in which patients were categorized into low- (score 0), intermediate- (score 1), and high-risk (scores 2-3) groups. The scoring system differentiated DFS and OS well (C-index = 0.65, 95% confidence interval, 0.59-0.72; and C-index = 0.65, 95% confidence interval, 0.59-0.72, respectively). CONCLUSIONS: The TSR is an independent prognostic factor, and our prognostic scoring system that incorporates this parameter exhibits good discriminative ability for both recurrence and survival in patients with 2018 FIGO stage IIIC cervical cancer after radical surgery. The TSR is a potentially novel clinicopathological variable for predicting the prognoses of these patients contingent on the validation of our findings.
OBJECTIVE: To determine the value of the tumor-stroma ratio (TSR) while identifying prognostic factors in patients with 2018 International Federation of Gynecology and Obstetrics (FIGO) stage IIIC squamous cell carcinoma of the cervix following primary radical surgery. METHODS: Three hundred eighty-four patients with node-positive squamous cell carcinoma of the cervix (2018 FIGO stage IIIC) who underwent radical surgery between January 2005 and December 2016 were included in this retrospective study. The TSRs were assessed on hematoxylin and eosin-stained tumor slides and classified as stroma-low (<50% stroma) or stroma-high (≥50% stroma). RESULTS: Sixty-seven patients were categorized as stroma-high; they had shorter disease-free survival (DFS) and overall survival (OS) periods than did their stroma-low counterparts. On multivariate analysis, a tumor size ≥4 cm, ≥3 metastatic lymph nodes, and stroma-high status were independent predictors of shorter DFS and OS. These factors were incorporated into a prognostic scoring system in which patients were categorized into low- (score 0), intermediate- (score 1), and high-risk (scores 2-3) groups. The scoring system differentiated DFS and OS well (C-index = 0.65, 95% confidence interval, 0.59-0.72; and C-index = 0.65, 95% confidence interval, 0.59-0.72, respectively). CONCLUSIONS: The TSR is an independent prognostic factor, and our prognostic scoring system that incorporates this parameter exhibits good discriminative ability for both recurrence and survival in patients with 2018 FIGO stage IIIC cervical cancer after radical surgery. The TSR is a potentially novel clinicopathological variable for predicting the prognoses of these patients contingent on the validation of our findings.
Authors: Sophie C Hagenaars; Kiki M H Vangangelt; Gabi W Van Pelt; Zsófia Karancsi; Rob A E M Tollenaar; Andrew R Green; Emad A Rakha; Janina Kulka; Wilma E Mesker Journal: Breast Cancer Res Treat Date: 2022-04-16 Impact factor: 4.624
Authors: Alhadi Almangush; Rasheed Omobolaji Alabi; Giuseppe Troiano; Ricardo D Coletta; Tuula Salo; Matti Pirinen; Antti A Mäkitie; Ilmo Leivo Journal: BMC Cancer Date: 2021-04-30 Impact factor: 4.430
Authors: Cor J Ravensbergen; Matthew Kuruc; Meaghan Polack; Stijn Crobach; Hein Putter; Hans Gelderblom; Devjit Roy; Rob A E M Tollenaar; Wilma E Mesker Journal: Cancers (Basel) Date: 2021-12-29 Impact factor: 6.639
Authors: Cor J Ravensbergen; Meaghan Polack; Jessica Roelands; Stijn Crobach; Hein Putter; Hans Gelderblom; Rob A E M Tollenaar; Wilma E Mesker Journal: Cells Date: 2021-10-28 Impact factor: 6.600